Clinical Approach to Medical Management of Type 2 Diabetes
Clinical Approach to Medical Management of Type 2 Diabetes
Clinical Approach to Medical Management of Type 2 Diabetes
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Bromocriptine<br />
• Ergot-derived dopamine agonist, unknown antidiabetic<br />
mechanism (presumably by increasing the hypotalamic<br />
dopamine levels and decreasing SNS activity)<br />
– A1c reduction ~0.4%<br />
– Dose 0.6-4.8 mg PO daily in AM within 2 hrs after waking<br />
– SE: nausea, dizziness, HA, syncope<br />
Bromocriptine<br />
N=80<br />
(1.6-4.8 mg/day)<br />
Placebo<br />
N=79<br />
HbA1c (%)<br />
•Baseline 9.0 8.8<br />
•Change from baseline -0.1 +0.3<br />
•Difference from placebo -0.4<br />
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf, accessed 04/04/2012
Change language